text
"['\n2. 주요 제품 및 서비스\n2-1. 주요 매출액 현황[의약품/바이오부문] \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0(단위: 백만원, %)\n매출유형\n품목명\n구체적 용도\n제37기\n제36기\n매출액\n비율\n매출액\n비율\n제품\n씨앤유캡슐\n소화기용제\n14,549\n10.6\n13,839\n11.2\n에페신/SR/에이스정\n근이완제\n4,428\n3.2\n5,205\n4.2\n명문로수바스타틴칼슘정\n고지혈증치료제\n3,599\n2.6\n3,574\n2.9\n명문아트로다캡슐\n퇴행성 관절질환치료제\n3,219\n2.3\n3,269\n2.6\n노피드캡슐\n고지혈증치료제\n1,161\n0.8\n1,102\n0.8\n기 타\n65,274\n47.6\n47,063\n38.2\n제품매출 계\n92,230\n67.3\n74,052\n60.1\n상품\n로젯정\n고지혈증 치료제\n10,019\n7.3\n8,483\n6.8\n뉴라렌정/캡슐/주\n뇌기능개선제\n3,812\n2.8\n4,217\n3.4\n트라펜정(세미/서방)\n소염진통제\n4,103\n3.0\n3,454\n2.8\n에스프롤정\n역류성 식도염치료제\n2,257\n1.6\n1,968\n1.6\n기 타\n24,686\n18.0\n31,001\n25.1\n상품매출 계\n44,877\n32.7\n49,125\n39.8\n합 \xa0 \xa0 \xa0 \xa0 \xa0계\n137,107\n100.0\n123,177\n100.0\n주) 별도재무제표기준으로 작성되었습니다.[서비스부문] \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0(단위: 백만원, %)\n구분\n제37기\xa0\n제36기\n제35기\n금액\n비율\n금액\n비율\n금액\n비율\n골프 코스 매출\n5,823\n72.9\n5,423\n71.2\n4,216\n72\n식음료 매출\n346\n4.3\n356\n4.8\n371\n6.3\n기타 매출\n1.825\n22.8\n1,790\n24.0\n1,267\n21.6\n합 \xa0 \xa0 \xa0 \xa0 \xa0계\n7,994\n100.0\n7,569\n100.0\n5,854\n100.0\n2. 주요제품(상품)의 가격변동 추이 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 (단위 : 원)\n순번\n구분\n품목명\n제37기\xa0\n제36기\n제35기\n1\n소화기용제\n씨앤유캡슐 (1C)\n289\n289\n289\n2\n고지혈증치료제\n로젯정 10/10mg (1T)\n1,251\n1,251\n1,251\n3\n근이완제\n에페신정 (1T)\n113\n113\n113\n4\n고지혈증치료제\n명문로수바스타틴 10mg (1T)\n612\n612\n612\n5\n골관절염치료제\n명문아트로다캅셀 50mg (1C)\n212\n212\n212\n6\n치매치료제\n셉트페질정10mg (1T)\n1,872\n1,872\n1,872\n주) 완제의약품의 가격 : 보험약가 기준 가격 주요변동원인 : 약가재평가, 선별등재시스템(PLS), 실거래가상환제 등\n']"
